Equities Updates on Top Gainers -- Research on E-Commerce China Dangdang, Neuralstem, Cytokinetics, and Nu Skin Enterprises
PR Newswire - Thu Apr 10, 12:30PM CDT
The US markets saw a positive sentiment on Wednesday, April 09, 2014, with the NASDAQ Composite closing at 4,183.90, up 1.72%, the Dow Jones Industrial Average ending the session at 16,437.18, up 1.11%, and the S&P 500 edging 1.09% higher to finish the trading session at 1,872.18. The session saw a positive impact from Information Technology, Health Care and Materials sectors along with a drag from Utilities and Telecommunication Services sectors. A number of stocks saw large movements, including E-Commerce China Dangdang Inc. (NYSE: DANG), Neuralstem Inc. (NYSE: CUR), Cytokinetics Inc. (NASDAQ: CYTK) and Nu Skin Enterprises Inc. (NYSE: NUS). Free technical research on DANG, CUR, CYTK and NUS can be downloaded upon signing up at:
Uptrend Call Working As Cytokinetics Stock Rises 11.9% (CYTK)
Comtex SmarTrend(R) - Thu Apr 10, 9:27AM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 2 months, Cytokinetics has returned 11.90% as of today's recent price of $9.78.
Nasdaq stocks posting largest percentage increases
AP - Wed Apr 09, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Enrollment in Expansion Phase of Trials, Results and Initiation of Phase 2 Studies and Stock Movements - Analyst Notes on Pfizer, Cytokinetics, Portola Pharmaceuticals, Volcano, and Array BioPharma
PR Newswire - Wed Apr 09, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Cytokinetics, Incorporated (NASDAQ: CYTK), Portola Pharmaceuticals, Inc. (NASDAQ: PTLA), Volcano Corporation (NASDAQ: VOLC), and Array BioPharma, Inc. (NASDAQ: ARRY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Cytokinetics to Present at the 13th Annual Needham Healthcare Conference
Thomson Reuters ONE - Tue Apr 01, 3:06PM CDT
South San Francisco, CA, April 1, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 1:40 PM Eastern Daylight Time at the Westin Grand Central Hotel in New York, New York.
Clinical Trial Initiation, Executive Appointments, Priced Offering, FDA Clearance, and Upcoming Conferences - Analyst Notes on Cytokinetics, Quintiles, Kindred, Volcano, and Novadaq
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cytokinetics, Inc. (NASDAQ: CYTK), Quintiles Transnational Holdings, Inc. (NYSE: Q), Kindred Healthcare, Inc. (NYSE: KND), Volcano Corporation (NASDAQ: VOLC), and Novadaq Technologies Inc. (NASDAQ: NVDQ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Cytokinetics Announces the Opening to Enrollment of the Expansion of COSMIC-HF
Thomson Reuters ONE - Fri Mar 28, 6:31AM CDT
Commencement of Next Stage in International Phase II Clinical Trial of Oral Formulation of Omecamtiv Mecarbil in Patients with Heart Failure
Cytokinetics Announces Initiation of Multiple Dose Phase I Clinical Trial of CK-2127107
Thomson Reuters ONE - Thu Mar 27, 6:31AM CDT
Commencement of Study Triggers Milestone Payment from Astellas
Cytokinetics Up 15.0% Since SmarTrend Uptrend Call (CYTK)
Comtex SmarTrend(R) - Wed Mar 19, 11:11AM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 1 month, Cytokinetics has returned 14.99% as of today's recent price of $10.05.
Cytokinetics Shares Up 24.0% Since SmarTrend's Buy Recommendation (CYTK)
Comtex SmarTrend(R) - Wed Mar 05, 9:27AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 3 weeks, Cytokinetics has returned 24.03% as of today's recent price of $10.84.
Stock Movements, Upcoming Conferences, Financial Results, and Public Offering Closings - Analyst Notes on Community Health Systems, United Therapeutics, Thoratec, AMRI, and Cytokinetics
PR Newswire - Wed Mar 05, 6:15AM CST
Editor Note: For more information about this release, please scroll to bottom.
Cytokinetics to Present at Upcoming Healthcare Conferences
Thomson Reuters ONE - Fri Feb 28, 3:01PM CST
South San Francisco, CA, February 28, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that members of its management team are scheduled to participate at the following healthcare conferences:
Multiple Insiders of Cytokinetics, Incorporated (CYTK)-NasdaqCM bought Shares of CYTK
M2 - Fri Feb 28, 8:34AM CST
Reported by InsiderCow.com at 2014-02-27 15:33:52 ET
Shares of CYTK Up 15.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 26, 9:28AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 2 weeks, Cytokinetics has returned 15.10% as of today's recent price of $10.06.
Cytokinetics Announces Closing of its Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
Thomson Reuters ONE - Tue Feb 25, 3:00PM CST
Trade-Ideas: Cytokinetics (CYTK) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Feb 21, 8:59AM CST
Trade-Ideas LLC identified Cytokinetics (CYTK) as a "dead cat bounce" (down big yesterday but up big today) candidate
Cytokinetics Announces pricing of $35.0 Million Public Offering of Common Stock
Thomson Reuters ONE - Thu Feb 20, 7:56AM CST
South San Francisco, CA, February 20, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the pricing of its previously announced underwritten public offering of 4,375,000 shares of its common stock at a price to the public of $8.00 per share. Cytokinetics anticipates its aggregate gross proceeds will be approximately $35.0 million before deducting the underwriting discount and estimated offering expenses payable by Cytokinetics. In addition, Cytokinetics has granted the underwriters a 30 day option to purchase up to an additional 656,250 shares of common stock under the same terms and conditions solely to cover over-allotments, if any. All of the shares in the offering are to be sold by Cytokinetics. The offering is expected to close on or about February 25, 2014, subject to the satisfaction of customary closing conditions.